-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Day One Biopharmaceutical Analyst Ratings
Day One Biopharmaceutical Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
02/03/2023 | — | Oppenheimer | Initiates Coverage On | → Perform | |
01/09/2023 | 185.06% | Goldman Sachs | $45 → $62 | Maintains | Buy |
01/09/2023 | 106.9% | Piper Sandler | $40 → $45 | Maintains | Overweight |
01/09/2023 | 106.9% | HC Wainwright & Co. | $35 → $45 | Maintains | Buy |
12/15/2022 | 60.92% | HC Wainwright & Co. | → $35 | Initiates Coverage On | → Buy |
12/14/2022 | 83.91% | Needham | → $40 | Initiates Coverage On | → Buy |
12/05/2022 | 106.9% | Goldman Sachs | → $45 | Initiates Coverage On | → Buy |
12/01/2022 | 56.32% | B of A Securities | → $34 | Initiates Coverage On | → Buy |
06/21/2022 | 83.91% | Piper Sandler | $35 → $40 | Maintains | Overweight |
06/14/2022 | 60.92% | Wedbush | $32 → $35 | Maintains | Outperform |
06/21/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
06/21/2021 | 37.93% | Wedbush | → $30 | Initiates Coverage On | → Outperform |
06/21/2021 | 74.71% | JP Morgan | → $38 | Initiates Coverage On | → Overweight |
06/21/2021 | 102.3% | Piper Sandler | → $44 | Initiates Coverage On | → Overweight |
What is the target price for Day One Biopharmaceutical (DAWN)?
The latest price target for Day One Biopharmaceutical (NASDAQ: DAWN) was reported by Oppenheimer on February 3, 2023. The analyst firm set a price target for $0.00 expecting DAWN to fall to within 12 months (a possible -100.00% downside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Day One Biopharmaceutical (DAWN)?
The latest analyst rating for Day One Biopharmaceutical (NASDAQ: DAWN) was provided by Oppenheimer, and Day One Biopharmaceutical initiated their perform rating.
When is the next analyst rating going to be posted or updated for Day One Biopharmaceutical (DAWN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Day One Biopharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Day One Biopharmaceutical was filed on February 3, 2023 so you should expect the next rating to be made available sometime around February 3, 2024.
Is the Analyst Rating Day One Biopharmaceutical (DAWN) correct?
While ratings are subjective and will change, the latest Day One Biopharmaceutical (DAWN) rating was a initiated with a price target of $0.00 to $0.00. The current price Day One Biopharmaceutical (DAWN) is trading at is $21.75, which is out of the analyst's predicted range.
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
02/03/2023 | — | Oppenheimer | Initiates Coverage On | → Perform | |
01/09/2023 | 185.06% | Goldman Sachs | $45 → $62 | Maintains | Buy |
01/09/2023 | 106.9% | Piper Sandler | $40 → $45 | Maintains | Overweight |
01/09/2023 | 106.9% | HC Wainwright & Co. | $35 → $45 | Maintains | Buy |
12/15/2022 | 60.92% | HC Wainwright & Co. | → $35 | Initiates Coverage On | → Buy |
12/14/2022 | 83.91% | Needham | → $40 | Initiates Coverage On | → Buy |
12/05/2022 | 106.9% | Goldman Sachs | → $45 | Initiates Coverage On | → Buy |
12/01/2022 | 56.32% | B of A Securities | → $34 | Initiates Coverage On | → Buy |
06/21/2022 | 83.91% | Piper Sandler | $35 → $40 | Maintains | Overweight |
06/14/2022 | 60.92% | Wedbush | $32 → $35 | Maintains | Outperform |
06/21/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
06/21/2021 | 37.93% | Wedbush | → $30 | Initiates Coverage On | → Outperform |
06/21/2021 | 74.71% | JP Morgan | → $38 | Initiates Coverage On | → Overweight |
06/21/2021 | 102.3% | Piper Sandler | → $44 | Initiates Coverage On | → Overweight |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
02/03/2023 | — | 奥本海默 | 启动覆盖范围开启 | → 表演 | |
01/09/2023 | 185.06% | 高盛 | 45 美元 → 62 美元 | 维护 | 买 |
01/09/2023 | 106.9% | 派珀·桑德勒 | 40 美元 → 45 美元 | 维护 | 超重 |
01/09/2023 | 106.9% | HC Wainwright & Co. | 35 美元 → 45 美元 | 维护 | 买 |
2022 年 12 月 15 日 | 60.92% | HC Wainwright & Co. | → 35 美元 | 启动覆盖范围开启 | → 购买 |
2022 年 12 月 14 日 | 83.91% | 尼德姆 | → 40 美元 | 启动覆盖范围开启 | → 购买 |
12/05/2022 | 106.9% | 高盛 | → 45 美元 | 启动覆盖范围开启 | → 购买 |
2022 年 1 月 12 日 | 56.32% | B of A 类证券 | → 34 美元 | 启动覆盖范围开启 | → 购买 |
2022 年 6 月 21 日 | 83.91% | 派珀·桑德勒 | 35 美元 → 40 美元 | 维护 | 超重 |
06/14/2022 | 60.92% | Wedbush | 32 美元 → 35 美元 | 维护 | 跑赢大盘 |
06/21/2021 | — | Cowen & Co. | 启动覆盖范围开启 | → 跑赢大盘 | |
06/21/2021 | 37.93% | Wedbush | → 30 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
06/21/2021 | 74.71% | 摩根大通 | → 38 美元 | 启动覆盖范围开启 | → 超重 |
06/21/2021 | 102.3% | 派珀·桑德勒 | → 44 美元 | 启动覆盖范围开启 | → 超重 |
What is the target price for Day One Biopharmaceutical (DAWN)?
Day One Biopharmaceutical(DAWN)的目标价格是多少?
The latest price target for Day One Biopharmaceutical (NASDAQ: DAWN) was reported by Oppenheimer on February 3, 2023. The analyst firm set a price target for $0.00 expecting DAWN to fall to within 12 months (a possible -100.00% downside). 10 analyst firms have reported ratings in the last year.
奥本海默于2023年2月3日公布了第一天生物制药(纳斯达克股票代码:DAWN)的最新目标股价。该分析公司将目标股价定为0.00美元,预计DAWN将在12个月内跌至12个月内(可能下跌-100.00%)。去年有10家分析公司公布了评级。
What is the most recent analyst rating for Day One Biopharmaceutical (DAWN)?
Day One Biopharmaceutical(DAWN)的最新分析师评级是多少?
The latest analyst rating for Day One Biopharmaceutical (NASDAQ: DAWN) was provided by Oppenheimer, and Day One Biopharmaceutical initiated their perform rating.
第一天生物制药(纳斯达克股票代码:DAWN)的最新分析师评级由奥本海默提供,第一天生物制药启动了其业绩评级。
When is the next analyst rating going to be posted or updated for Day One Biopharmaceutical (DAWN)?
Day One Biopharmaceutical(DAWN)的下一份分析师评级何时发布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Day One Biopharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Day One Biopharmaceutical was filed on February 3, 2023 so you should expect the next rating to be made available sometime around February 3, 2024.
分析师在进行了广泛的研究后得出了股票评级,其中包括浏览公开财务报表,与第一天生物制药公司的高管和客户交谈,以及听取财报电话会议。大多数分析师每三个月做一次这样的评级,因此每家公司每年应该获得4次评级。第一天生物制药的最新评级是在2023年2月3日公布的,因此您应该预计下一个评级将在2024年2月3日左右公布。
Is the Analyst Rating Day One Biopharmaceutical (DAWN) correct?
分析师对第一天生物制药(DAWN)的评级是否正确?
While ratings are subjective and will change, the latest Day One Biopharmaceutical (DAWN) rating was a initiated with a price target of $0.00 to $0.00. The current price Day One Biopharmaceutical (DAWN) is trading at is $21.75, which is out of the analyst's predicted range.
尽管评级是主观的,并且会发生变化,但最新的第一天生物制药(DAWN)评级最初设定为0.00美元至0.00美元。目前第一天生物制药(DAWN)的交易价格为21.75美元,超出了分析师的预期区间。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧